SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ANDRX (ADRX)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: James Silverman who wrote (94)6/7/1998 1:55:00 PM
From: Mike Moran  Read Replies (2) of 127
 
<< If MDIX were a healthy company I do not think they would resort to posting their suit on the internet. Andrx has already sued them for slander, so unless MDIX can prove Andrx guilt, it would seem they are only providing more fuel for Andrx. >>

Any civil litigator will point out that as long as MDIX confines its name calling of ADRX to allegations contained in a civil complaint, they are immune from libel and slander prosecution. Of course, the allegations must contain minimally supportable claims, and they must pass a sniff test when, as expected, ADRX (in this case) attacks the complaint.

I will also point out that ADRX was the first to post their responses and attacks of MDIX on the Internet. You will find all three of the ADRX news releases on the net. You won't find the "slander" complaint because it only alleges that MDIX called them names in a news release and they have suffered damages as a result. Those supposed damages (resulting from the MDIX news release) became impossible to prove when ADRX stock recently reached $39. Yes, I know the stock is now in the low $30s, but that too proves that the March 18 MDIX news release had nothing to do with the ADRX stock price.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext